BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 106 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $249,000 | -61.9% | 1,706 | -63.7% | 0.00% | -71.4% |
| Q3 2021 | $653,000 | +12.2% | 4,700 | -21.7% | 0.01% | +16.7% |
| Q2 2021 | $582,000 | -33.8% | 6,000 | -55.6% | 0.01% | -64.7% |
| Q3 2020 | $879,000 | +42.0% | 13,525 | +19.0% | 0.02% | +13.3% |
| Q4 2019 | $619,000 | -84.6% | 11,361 | -88.2% | 0.02% | -87.3% |
| Q3 2019 | $4,026,000 | +1543.3% | 96,500 | +1623.2% | 0.12% | +1211.1% |
| Q2 2019 | $245,000 | -55.1% | 5,600 | -47.2% | 0.01% | -52.6% |
| Q1 2019 | $546,000 | -92.3% | 10,600 | -94.5% | 0.02% | -93.1% |
| Q4 2018 | $7,123,000 | +97.0% | 192,600 | +100.0% | 0.27% | +70.2% |
| Q3 2018 | $3,616,000 | +19.0% | 96,300 | -18.3% | 0.16% | -29.4% |
| Q1 2018 | $3,038,000 | +426.5% | 117,919 | +451.2% | 0.23% | +385.1% |
| Q4 2017 | $577,000 | – | 21,394 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
| Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
| ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
| Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
| Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
| Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |